PHVS · NASDAQ · Biotechnology

Pharvaris (PHVS)

Develops oral deucrictibant formulations to treat and prevent hereditary angioedema attacks.

$34.91
After hours−0.28 (−0.80%)
At close$35.19(−2.30%)